ALGORX AND CORGENTECH ANNOUNCE DATA FROM TRIAL OF ALGRX 3268
AlgoRx Pharmaceuticals and Corgentech have reported positive data from the first of two ongoing Phase III trials of ALGRX 3268 -- a fast-acting local anesthetic administered into the skin by powder injection and aimed at reducing pain associated with venipuncture procedures (blood draws and intravenous line placements). The primary endpoint of the 574-pediatric patient trial was achieved, showing that treatment with ALGRX 3268 demonstrated statistically significantly less pain compared with the placebo group. ALGRX 3268 was well-tolerated and demonstrated no significant safety issues.
This study was conducted at six centers in the U.S. in patients 3 to 18 years of age. A total of 574 patients were administered a placebo (285 patients) or the local anesthetic, ALGRX 3268 (289 patients), one to three minutes before having procedures that required either venipuncture or intravenous cannulation. A second Phase III trial of ALGRX 3268 with an identical clinical trial protocol is being conducted in approximately 500 patients.